ChipDX was an online data analysis platform I developed in 2010 to analyse genomic data from cancer patients and generate accurate, clinically-useful results.
After uploading a patient’s raw data file, the user could select from one or more analysis modules, including data quality control, prediction of tumour recurrence/survival, treatment response or identification of a metastatic tumour’s primary tissue of origin.
ChipDX.com was developed using Microsoft .NET, SQL Server, R, Bioconductor and various Affymetrix components. More information can be found in this flyer (5MB PDF)
The system can be accessed for research-use-only at www.chipdx.com and is now owned by Signal Genetics, where it is used to manage the analysis and reporting of a proprietary genetic test for patients diagnosed with multiple myeloma; MyPRS.
Publications:
- Design and multiseries validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival
RK Van Laar, The Journal of Molecular Diagnostics 13 (3), 297-304 - An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer
RK Van Laar, British journal of cancer 103 (12), 1852 - Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer
RK Van Laar, BMC medical genomics 5 (1), 30